Citi raised the firm’s price target on Amylyx (AMLX) to $20 from $12 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $19 from $10 at Baird
- Amylyx price target raised to $16 from $14 at BofA
- Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target
- Amylyx price target raised to $25 from $17 at Guggenheim
- Amylyx Pharmaceuticals Announces $164 Million Stock Offering